Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
Multiple Myeloma Hub
Impact of DARATUMUMAB in Maintenance Therapy for Newly Diagnosed Multiple Myeloma Patients
Exploring the benefits of adding DARATUMUMAB to maintenance therapy for newly diagnosed multiple myeloma patients. The chapter illustrates increased rates of minimal residual disease negativity, enhanced progression-free survival, and manageable toxicity profile.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
